A review of tuberculosis: Focus on bedaquiline

American Journal of Health-System Pharmacy

Volumn 70, Issue 22, 2013, Pages 1984-1994

  Chan, Bonnie ^a   Khadem, Tina M ^b,c   Brown, Jack ^b,c  

^a PHILADELPHIA COLLEGE OF OSTEOPATHIC MEDICINE   (United States)

^b ST JOHN FISHER COLLEGE   (United States)

^c URMC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; BEDAQUILINE; CIPROFLOXACIN; CYCLOSERINE; EFAVIRENZ; ETHIONAMIDE; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; QUINOLINE DERIVATIVE; TUBERCULOSTATIC AGENT;

ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACTERIAL CELL WALL; BACTERIAL LOAD; BACTERIAL VIRULENCE; CONFORMATIONAL TRANSITION; CROSS RESISTANCE; DIASTEREOISOMER; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG INDICATION; DRUG SENSITIVITY; HEALTH CARE QUALITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIVER DISEASE; LUNG TUBERCULOSIS; LYSOSOME; MACROPHAGE; MALNUTRITION; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR WEIGHT; MULTICENTER STUDY (TOPIC); MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS; NEOLITHIC; PHAGOSOME; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICIAN; PLASMA CONCENTRATION-TIME CURVE; PROTON TRANSPORT; QT PROLONGATION; REVIEW; SHORT COURSE THERAPY; SIDE EFFECT; SPONTANEOUS MUTATION; TREATMENT DURATION; TUBERCULIN TEST; TUBERCULOSIS; TUBERCULOSIS CONTROL; WORK ENVIRONMENT; DRUG APPROVAL; DRUG COMBINATION; FOOD AND DRUG ADMINISTRATION; MOLECULARLY TARGETED THERAPY; PREVALENCE; UNITED STATES;

ANTITUBERCULAR AGENTS; DIARYLQUINOLINES; DRUG APPROVAL; DRUG THERAPY, COMBINATION; HUMANS; MOLECULAR TARGETED THERAPY; PREVALENCE; TUBERCULOSIS, MULTIDRUG-RESISTANT; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84905132609     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp130199     Document Type: Review

References (57)

1. Kapur V, Whittam TS, Musser JM. Is Mycobacterium tuberculosis 15,000 years old? J Infect Dis. 1994; 170:1348-9.
2. Daniel TM. The history of tuberculosis. Respir Med. 2006; 100:1862-70.
3. Formicola V, Milanesi Q, Scarsini C. Evidence of spinal tuberculosis at the beginning of the fourth millennium BC from Arene Candide cave (Liguria, Italy). Am J Phys Anthropol. 1987; 72:1-6.
4. Canci A, Minozzi S, Borgognini Tarli SM. New evidence of tuberculous spondylitis from Neolithic Liguria (Italy). Int J Osteoarchaeol. 1996; 6:497-501.
5. Hershkovitz I, Donoghue HD, Minnikin DE et al. Detection and molecular characterization of 9,000-year-old Mycobacterium tuberculosis from a Neolithic settlement in the Eastern Mediterranean. PLoS One. 2008; 3:e3426.
6. Herzog H. History of tuberculosis. Respiration. 1998; 65:5-15.
7. Lonnroth K, Castro KG, Chakaya JM et al. Tuberculosis control and elimination 2010-50: cure, care, and social development. Lancet. 2010; 375:1814-29.
8. Vynnycky E, Fine PE. Interpreting the decline in tuberculosis: the role of secular trends in effective contact. Int J Epidemiol. 1999; 28:327-34.
9. World Health Organization. Global tuberculosis report 2012. www.who.int/tb/publications/global-report/en/ (accessed 2013 Aug 12).
10. Stop TB Partnership/World Health Organization. The global plan to stop TB 2011-2015. www.stoptb.org/assets/documents/global/plan/TB-GlobalPlanToStopTB2011-2015.pdf (accessed 2013 Aug 12).
11. World Health Organization. Global tuberculosis control 2011. http://whqlibdoc.who.int/publications/2011/9789241564380-eng.pdf (accessed 2013 Aug 12).
12. Barry CE. Interpreting cell wall 'virulence factors' of Mycobacterium tuberculosis. Trends Microbiol. 2001; 9:237-41.
13. Barry MC, Mdluli K. Drug sensitivity and environmental adaptation of mycobacterial cell wall components. Trends Microbiol. 1996; 4:275-8.
14. Deretic V, Singh S, Master S et al. Mycobacterium tuberculosis inhibition of phagolysosome biogenesis and autophagy as a host defence mechanism. Cell Microbiol. 2006; 8:719-27.
15. Rüsch-Gerdes S. Epidemiology of resistant tuberculosis in Europe. Infection. 1999; 7(suppl 2):S17-8.
16. The extent and management of drug-resistant tuberculosis: the American experience. In: Dooley SW, Simone PM, eds. Clinical tuberculosis. New York: Chapman and Hall; 1994:171-89.
17. Johnson R, Streicher EM, Louw GE et al. Drug resistance in Mycobacterium tuberculosis. Curr Issues Mol Biol. 2006; 8:97-111.
18. Pfyffer GE. Drug-resistant tuberculosis: resistance mechanisms and rapid susceptibility testing. Schweiz Med Wochenschr. 2000; 130:1909-13.
19. Zignol M, Hosseini MS, Wright A et al. Global incidence of multidrug-resistant tuberculosis. J Infect Dis. 2006; 194:479-85.
20. Zhang Y, Young D. Molecular genetics of drug resistance in Mycobacterium tuberculosis. J Antimicrob Chemother. 1994; 34:313-9.
21. Ramaswamy S, Musser JM. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuber Lung Dis. 1998; 79:3-29.
22. Falzon D, Jaramillo E, Schünemann HJ et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J. 2011; 38:516-28.
23. Drobniewski FA, Pozniak AL. Molecular diagnosis, detection of drug resistance and epidemiology of tuberculosis. Br J Hosp Med. 1996; 8:204-8.
24. Scott LE, McCarthy K, Gous N et al. Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study. PLoS Med. 2011; 8:e1001061.
25. World Health Organization. Rapid implementation of the Xpert MTB/RIF diagnostic test: technical and operational "how-to" practical considerations. http://whqlibdoc.who.int/publications/2011/9789241501569-eng.pdf (accessed 2013 Aug 1).
26. Connolly LE, Edelstein PH, Ramakrishnan L. Why is long-term therapy required to cure tuberculosis? PLoS Med. 2007; 4:e120.
27. Caminero JA, Sotgiu G, Zumla A et al. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis. 2010; 10:621-9.
28. Mitnick CD, Castro KG, Harrington M et al. Randomized trials to optimize treatment of multidrug-resistant tuberculosis. PLoS Med. 2007; 4:e292.
29. Espinal MA, Kim SJ, Suarez PG et al. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA. 2000; 283:2537-45.
30. Aziz MA, Wright A, Laszlo A et al. Epidemiology of antituberculosis drug resistance (the Global Project on Antituberculosis Drug Resistance Surveillance): an updated analysis. Lancet. 2006; 368:2142-54.
31. World Health Organization. Treatment of tuberculosis: guidelines - 4th ed. http://whqlibdoc.who.int/publications/2010/9789241547833-eng.pdf (accessed 2013 Aug 1).
32. World Health Organization. Management of MDR-TB: a field guide: a companion document to guidelines for programmatic management of drugresistant tuberculosis: integrated management of adolescent and adult illness (IMAI). http://whqlibdoc.who.int/publications/2009/9789241547765-eng.pdf (accessed 2013 Aug 1).
33. Ziganshina LE, Squire SB. Fluoroquinolones for treating tuberculosis. Cochrane Database Syst Rev. 2008; 1:CD004795.
34. Gumbo T. Chemotherapy of tuberculosis, Mycobacterium avium complex disease, and leprosy. In: Brunton LL, Chabner BA, Knollmann BC, eds. Goodman & Gilman's the pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill; 2011.
35. World Health Organization. Drug-resistant tuberculosis now at record levels. www.who.int/mediacentre/news/releases/2010/drug-resistant-tb-20100318/en/ (accessed 2013 Jan 27).
36. Dooley KE, Mitnick CD, Ann DeGroote M et al. Old drugs, new purpose: retooling existing drugs for optimized treatment of resistant tuberculosis. Clin Infect Dis. 2012; 55:572-81.
37. Villemagne B, Crauste C, Flipo M et al. Tuberculosis: the drug development pipeline at a glance. Eur J Med Chem. 2012; 51:1-16.
38. Sirturo (bedaquiline) package insert. Titusville, NJ: Janssen Therapeutics, Division of Johnson & Johnson; 2012 Dec.
39. Voelker R. MDR-TB has new drug foe after fast-track approval. JAMA. 2013; 309:430. News.
40. Barry CE. Unorthodox approach to the development of a new antituberculosis therapy. N Engl J Med. 2009; 360:2466-7.
41. Tyagi JS, Sharma D. Mycobacterium smegmatis and tuberculosis. Trends Microbiol. 2002; 10:68-9.
42. Andries K, Verhasselt P, Guillemont J et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science. 2005; 307:223-7 with supporting online material.
43. Protopopova M, Bogatcheva E, Nikonenko B et al. In search of new cures for tuberculosis. Med Chem. 2007; 3:301-16.
44. Matteelli A, Carvalho AC, Dooley KE et al. TMC207: the first compound of a new class of potent anti-tuberculosis drugs. Future Microbiol. 2010; 5:849-58.
45. Haagsma AC, Podasca I, Koul A et al. Probing the interaction of the diarylquinoline TMC207 with its target mycobacterial ATP synthase. PLoS One. 2011; 6:e23575.
46. Haagsma AC, Abdillahi-Ibrahim R, Wagner MJ et al. Selectivity of TMC207 towards mycobacterial ATP synthase compared with that towards the eukaryotic homologue. Antimicrob Agents Chemother. 2009; 53:1290-2.
47. Rastogi N, Goh KS, David HL. Drug susceptibility testing in tuberculosis: a comparison of the proportion methods using Lowenstein-Jensen, Middlebrook 7H10 and 7H11 agar media and a radiometric method. Res Microbiol. 1989; 140:405-17.
48. Clinical and Laboratory Standards Institute. Susceptibility testing of mycobacteria, Nocardiaceae, and other aerobic actinomycetes; approved standard, 2nd ed. CLSI document M24-A2. Wayne, PA: Clinical and Laboratory Standards Institute; 2011.
49. Martin A, Portaels F, Palomino JC. Colorimetric redox-indicator methods for the rapid detection of multidrug resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis. J Antimicrob Chemother. 2007; 59:175-83.
50. Rustomjee R, Diacon AH, Allen J et al. Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis. Antimicrob Agents Chemother. 2008; 52:2831-5.
51. Diacon AH, Pym AP, Grobush M et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med. 2009; 360:2397-405.
52. Diacon AH, Donald PR, Pym A et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: longterm outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother. 2012; 56:3271-6.
53. Dooley KE, Park JG, Swindells S et al. Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Group Study A5267. J Acquir Immune Defic Syndr. 2012; 59:455-62.
54. Janssen Pharmaceutical Companies. Anti-infective drugs advisory committee meeting. Briefing document. TMC207 (bedaquiline). Treatment of patients with MDR-TB. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM329260.pdf (accessed 2013 Mar 23).
55. Food and Drug Administration. FDA news release. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm333695.htm (accessed 2013 Mar 23).
56. Gomez JE, McKinney JD. Mycobacterium tuberculosis persistence, latency, and drug tolerance. Tuberculosis. 2004; 84:29-44.
57. World Health Organization. The use of bedaquiline in the treatment of multidrug-resistant tuberculosis: interim policy guidance. WHO/HTM/TB/2013.6. http://apps.who.int/iris/bitstream/10665/84879/1/9789241505482-eng.pdf (accessed 2013 Aug 12).